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Abstract 
Background: The reduced glomerular filtration rate in the advanced stages of chronic kidney 
disease (CKD) leads to plasma accumulation of uremic retention solutes including proteins. It 
has been hypothesized that these changes may, at least in part, be responsible for CKD-
associated morbidity and mortality. However, most studies focused on the role of individual 
proteins while a holistic, large-scale, integrative approach may generate significant additional 
insight.  
Methods: In a discovery study, we analysed the plasma proteomes of patients with stage 2-3 
CKD (n=14) and stage 5 CKD with hemodialysis (HD)(n=15), using high-resolution LC-MS/MS 
analysis. Selected results were validated in cohort of 40 patients with different CKD stages with 
or without HD, using ELISA. 
Results: Of a total of 2054 detected proteins, 127 displayed lower, while 206 displayed higher 
abundance in plasma of patients on HD. Molecular pathway analysis confirmed modification of 
known processes involved in CKD complications including decreased hemostasis and increased 
inflammation, complement activation and vascular damage. In addition, we identified the plasma 
increase during CKD progression of lysozyme C and leucine-rich alpha-2 glycoprotein, two 
proteins related to vascular damage and heart failure not yet found to be associated to CKD. 
Interestingly high level of leucine-rich alpha-2 glycoprotein was associated with higher mortality 
in stage 5 CKD patients on HD.  
Conclusions: This study provides for the first time comprehensive assessment of CKD plasma 
proteome, contributes to new knowledge and potential markers in the field of late stage CKD and 
will serve as a basis for future studies investigating the relevance of these molecules in CKD-
associated morbidity and mortality. 
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Short summary: Plasma proteome analysis identified >300 proteins with modified abundance in 
patients on hemodialysis. Systems biology analysis and validation of key-proteins with ELISA 
suggested the association of these proteins to processes involved in the morbidity and mortality 
encountered in late stage CKD and identified potential new targets.  
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Introduction 
Chronic kidney disease (CKD) is characterized by progressive loss of renal function, with 
the final stage being end-stage renal disease (ESRD)1. At this stage, patients require permanent 
renal replacement therapy, i.e. hemodialysis (HD)/peritoneal dialysis (PD) or transplantation1. As 
kidney function declines, there is a progressive increase in both mortality and co-morbidities, 
such as cardiovascular complications 2-6. 
The molecular mechanisms involved in CKD and ESRD complications are complex and 
comprise coagulation abnormalities, endothelial dysfunction, vascular calcification due to 
impaired calcium and phosphate metabolism, increased oxidative and metabolic stress and 
inflammation7-10. The reduced glomerular filtration rate (GFR) in the advanced stages of CKD 
affects blood clearance and leads to subsequent accumulation of organic products (uremic 
retention solutes) and drugs that are normally metabolized or excreted by the kidney. Such 
uremic retention solutes include proteins, and may induce toxic effects11, 12. Significant changes 
in the blood protein composition have been reported in the past13-17, and it has been hypothesized 
that these changes in plasma proteins may, at least in part, be responsible for CKD-associated 
morbidity and mortality13, 14, 18. However these different studies mostly focused on the role of 
individual proteins and this promising yet disparate molecular evidence indicates a clear need for 
a holistic, large-scale approach. Plasma proteomics (i.e. analysis of the total plasma protein 
content) could be of particular interest to provide an integrated view and better understanding of 
CKD-associated complications. The recent advancement in proteomics technologies and 
software solutions have enabled assessing highly complex samples with high validity19, 20, 
indicating that high-resolution plasma proteome analysis should inform about CKD-associated 
molecular changes.  
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The rationale of the present study was to apply untargeted high-resolution plasma 
proteome analysis to investigate molecular changes associated with CKD. Our aim was to 
identify proteins with altered plasma levels and estimate the functional consequences of such 
changes. 
 
Material and Methods 
Patients 
The discovery cohort consisted of 29 patients with CKD. Fourteen CKD patients not 
treated with HD were recruited from the Department of Nephrology, Transplantation and 
Dialysis of the University Hospital of Montpellier and the Public Hospital of Sète. Fifteen 
patients on maintenance HD were recruited from the Néphrologie Dialyse Saint Guilhem 
Dialysis Unit in Sète. Recruitment was performed between February and June of 2008. The study 
was approved by the Comité de Protection des Personnes of Montpellier and declared to the 
French Ministry (reference number DC-2008–417).  
 The validation cohort consisted out of 32 CKD patients and 8 healthy controls selected 
from the sample collection of the Nephrology Department of the Ghent University Hospital, 
Belgium. Subjects were sampled under fasting conditions between January 2011 and July 2012. 
The study was approved by the local ethical committee (Belgian registration number 
B67020107926). The study was in accordance with the principles of the Declaration of Helsinki. 
Written informed consent was obtained from all participants before sampling.  
Patients on hemodialysis underwent either hemodialysis or online-hemodiafiltration 3 
times 4 hours a week. The quality of the dialysis fluid met the ultrapure standards (bacteria <0.1 
CFU/ml, endotoxin <0.03 EU/ml) as checked on a regular basis. Plasma samples were collected 
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prior to dialysis, before anticoagulant administration. One patient on home hemodialysis was 
sampled when consulting the out-patient clinic. 
K-EDTA-plasma samples were processed immediately after collection and stored at –
80°C. Urine protein, C-reactive protein and creatinine concentrations were determined by routine 
techniques by the hospital laboratory. eGFR was calculated based on serum creatinine using the 
CKD-EPI creatinine equation. Proteinuria was determined using urine dipstick or with >0.25g 
protein/g creatinine. 
 
Sample preparation for proteomic analysis 
Ten μL of thawed plasma sample was diluted with 90 μL 0.1% sodium dodecyl sulfate, 20mM 
dithiothreitol, and 0.1 M TrisHCl (pH=7.6). The sample was sonicated at room temperature for 
30 minutes, followed by denaturation at 95°C for 3 min. Samples were subsequently incubated 
with 50 mM Iodoacetamide at room temperature for 30 min in the dark followed by the addition 
of ammonium bicarbonate buffer solution (300 μL, 50mM), applied to NAP-5 column, and 
eluted with 1 mL of 50mM ammonium bicarbonate buffer solution. 
Twenty μg of lyophilized trypsin was added to 50 μL of activation buffer solution, and 2 μL of 
this solution was added to the eluted sample. Trypsin digestion was carried out overnight at a 
temperature of 37°C. Samples were then lyophilized, stored at 4°C and resuspended in 100 μL 
HPLC-grade H2O shortly before mass spectrometry analysis. 
 
Proteome analysis  
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The plasma extracts (5 μl) were analysed by nanoflow LC-MS/MS using a Orbitrap velos FTMS 
as per19. The gradient was run from at 1% B for 5 mins rising to 25% B after 360 mins then on to 
65% B after 480 mins.  
 
Proteomics data processing 
Peptide analysis was performed using SEQUEST against the Human Uniprot Database as per19. 
The relative quantitative analysis was performed based on the peptide area values. Before 
analysis, ppm-normalization of peptide areas was conducted.  
Normalized mass-peak area = Peptide mass-peak area / Total sample mass-peak area x 106 
Protein abundance was calculated as the sum of all normalized peptide areas for the given 
protein. Proteins covered by at least two valid peptides were considered valid. Mean protein 
abundance in the CKD2-3 group was compared to the mean protein abundance in the ESRD/HD 
group. Protein entries were mapped to the SwissProt database using either the mapping service 
provided by UniProt or via Blast searching (web.expasy.org/blast/) and merged according to the 
SwissProt names.  
 
ELISA 
Lysozyme C (Abcam (ab108880)), Complement factor D (R&D Systems (DFD00)), Leucine-
rich alpha-2-glycoprotein (Cusabio (CSB-E12962h)) and histidine-rich glycoprotein (Cusabio 
(CSB-E13159h)) were quantified by ELISA according to manufacturer's guidelines. Samples 
were analysed using the EL808 Ultra Microplate Reader from Bio-Tek Instruments (Winooski, 
VT) using KC4V3.0 Analysis Software. 
 
Functional analysis 
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Functional analysis was performed with Ingenuity Pathway Analysis (Qiagen) and Cytoscape 
(version 3.0.2; ClueGO plugin version 2.0.6) software. Individual analyses were performed by 
comparison of up-regulated versus down-regulated proteins, thereby eliminating common 
terminology-clusters associated with both conditions, using the GO-class of biological functions.  
 
Statistical analysis 
Statistical analysis was performed using Graph Pad Prism 5.0 software. F-test was performed to 
test for data distribution. When data were normally distributed, parametric t-test was performed; 
otherwise, the statistical analysis was performed using Mann-Whitney test or Wilcoxon signed 
rank test. Multiple hypotheses testing correction was performed using Benjamini-Hochberg test 
for false discovery rate. Comparison of survival curves was performed using Log-rank (Mantel-
Cox) test. 
 
Results  
 
Plasma proteome analysis  
We studied the plasma proteome of 14 patients with moderate CKD (stage 2 and 3, 
CKD2-3 group) and 15 patients on hemodialysis for at least one year (CKD5/HD group) (Table 
1). A schematic of the design is given in Figure 1. LC-MS/MS analysis enabled identification of 
9017 peptides (Supplementary Table 1), representing a total of 2054 unique proteins quantified 
using a label-free approach (Supplementary Table 2). To assess the validity of the quantification 
strategy, the reported concentration of 20 high abundant plasma proteins21-23 (Supplementary 
Table 3) was compared to their respective relative abundance in the LC-MS/MS experiment 
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(normalized-ppm mass-peak area, arbitrary units). As evident from Figure 2A significant 
correlation between existing data and LC-MS/MS quantification was observed (CKD2-3 
Spearman r = 0.8480, p<0.0001, CKD5/HD Spearman r = 0.7889, p<0.0001). A further 
validation of the plasma proteome-based approach was obtained by measuring C-reactive protein 
(CRP). We observed significant correlation between quantitative measurement of CRP obtained 
by routine laboratory testing (Table 1) and semi-quantitative LC-MS/MS abundance in the 
discovery cohort (Figure 2B), confirming the validity of the approach.  
 
Plasma proteome changes in CKD5/HD versus CKD2-3 patients 
When comparing the 15 datasets from patients on HD with the 14 from patients at early 
stage CKD, we identified 333 proteins as significantly different between the two groups, 127 
with lower and 206 with higher abundance in CKD5/HD compared to CKD2-3 (Supplementary 
Table 2). Upon correction for multiple testing, 39 of the 333 remained significant (Table 2). To 
exclude bias introduced by age or gender, we also investigated an age- and sex-matched 
subcohort of 7 CKD2-3 patients and 7 CKD5/HD patients (Table 1). Although this subcohort 
comparison is of lower statistical power, the initial results could be generally confirmed (Table 
2).  
Using LC-MS/MS, we confirmed increased abundance of 7 of 39 well-characterized 
uremic toxins11, 12 including beta-2-microglobulin and prostaglandin-H2 D-isomerase, while two 
of them were detected but showed unmodified abundance (i.e. immunoglobulins kappa and 
lambda) (Supplementary Table 4).  
 
Pathway analysis 
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Functional analysis of the 333 modified plasma proteins was performed using Gene 
Ontology (GO) and Ingenuity Pathway Analysis (IPA) software. The pathways with the highest 
modification scores included acute phase response signaling and complement and coagulation 
systems (Figure 3-4, Supplementary Table 5). Other pathways included platelet degranulation, 
calcium ion-dependent exocytosis, response to selenium ion, liver X receptor (LXR)/retinoid R 
receptor (RXR) activation, atherosclerosis signaling and production of nitric oxide (NO) and 
reactive oxygen species (ROS) (Supplementary Table 5).  
Of the 33 proteins associated with the complement system, 24 were detected in the 
plasma using LC-MS/MS. Among those 5 were significantly increased in abundance in the 
plasma of patients at CKD5/HD compared to CKD2-3 (Figure 3A), suggesting activation of the 
complement system in advanced CKD. On the other hand, 23 out of 35 proteins associated with 
the coagulation system were detected in the plasma using LC-MS/MS (not shown), and levels of 
5 were significantly modified, 3 with lower, and 2 with higher abundance in CKD5/HD 
compared to CKD2-3 (Figure 3B). From a total of 169 proteins associated with acute phase 
response signaling in Ingenuity database, 62 were detected in plasma and 17 were significantly 
modified in CKD5/HD patients (Figure 4). Most of these changes were in accordance with the 
activation of the pathway (Figure 4): 9 proteins known to be increased in the plasma during the 
acute phase response were found to be more abundant, and 4 known to be decreased were found 
to be less abundant in CKD5/HD compared to CKD2-3 (Figure 4). In particular, CRP levels 
determined by LC-MS/MS or routine analysis showed similar increase in the plasma of 
CKD5/HD patients compared to CKD2-3 (Figure 4, Bold and Table 1), confirming activation of 
the acute phase response in CKD. Of note, the same analysis was performed after exclusion of 6 
patients of the CKD5/HD group with highest CRP values and this lead to same results.   
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Validation of newly identified plasma proteins using ELISA 
We next aimed to validate key novel proteins in an independent cohort of healthy controls 
and patients with stage 3b (CKD3b), stage 4 (CKD4), and stage 5 CKD not on HD (CKD5 no 
HD) and on HD (CKD5/HD)(n=8/group), all matched for age and gender (Table 1) using 
ELISA. We confirmed that the abundance of complement factor D, lysozyme C and leucine-rich 
alpha-2 glycoprotein were significantly increased in plasma of CKD5 patients compared to 
controls. We further showed that their abundance progressively increased during CKD 
progression (Figure 5A-5C). We also demonstrated that protein levels were increased in the 
CKD5/HD group compared to CKD5 not on dialysis (Figure 5E-5G). We could not validate LC-
MS/MS change for histidine-rich glycoprotein (Figure 5D and 5H). We further correlated plasma 
concentrations of the proteins with the eGFR of the patients. Complement factor D (r=-0.9084, 
p<0.0001), lysozyme C (r=-0.7115, p<0.0001) and leucine-rich alpha-2 glycoprotein (r=-0.8236, 
p<0.0001) were inversely correlated with eGFR while histidine-rich glycoprotein showed no 
significant correlation (r=-0.0046, n.s.)(Supplementary Figure). 
 
Association of complement factor D, lysozyme C, leucine-rich alpha-2 glycoprotein and 
histidine-rich glycoprotein to mortality in CKD5/HD patients 
We next assessed the association of complement factor D, lysozyme C, leucine-rich 
alpha-2 glycoprotein and histidine-rich glycoprotein to the occurrence of all-cause mortality in 
CKD patients after a follow-up period of 3.14±0.14 years post sampling (Figure 6). In the 
discovery cohort, no mortality was observed in the CKD2-3 patient group. From the 15 patients 
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of the CKD5/HD group, two patients were excluded as one was transplanted and one was lost for 
follow-up. Among the 13 remaining patients, 10 died and 3 were still alive at the last follow-up. 
We determined the median LC-MS/MS abundance as the threshold for the four proteins. We 
observed that high abundance of leucine-rich alpha-2 glycoprotein was significantly associated 
with higher mortality in patients with CKD5 on hemodialysis compared to patients with low 
leucine-rich alpha-2 glycoprotein abundance (Figure 6C). Level of leucine-rich alpha-2 
glycoprotein was neither affected by age (73.86±4.37 and 71.33±6.15 years old in low versus 
high, p>0,05) nor time on dialysis (2±1.26 and 2±1.15 years in low versus high, p>0.05).  
 
Discussion 
The aim of the present study was to assess global plasma protein changes in late stage 
CKD patients and identify those proteins associated to CKD progression. The knowledge 
provided by this global approach is likely to help in progressing in our understanding of the 
pathophysiology of the different aspects of CKD and in recognizing those of prognosis value. To 
this aim, we compared the plasma proteome changes in patients with moderate CKD (stage 2 and 
3) to patients with advanced CKD undergoing HD using LC-MS/MS (Figure 1).  
Uremic toxins are solutes normally excreted by the kidneys, which accumulate and 
negatively impact biologic functions when renal function declines. Reviews from the European 
Uremic Toxin Work Group listed and classified 39 uremic retention proteins and their normal 
and uremic concentrations, as measured with antibody-based techniques, such as ELISA or 
radioimmunoassay11, 12. In our study, we confirmed the accumulation of seven of these well-
known uremic solutes (e.g. beta-2-microglobulina and prostaglandin-H2 D-isomerase) out of the 
333 proteins that were significantly different between the two groups. The technology did not 
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allow the detection of the other uremic toxins most likely due to their very low molecular weight 
(e.g. proenkephalin-A) and/or their very low abundance (e.g. fibroblast growth factor 23) and the 
masking effect of highly abundant plasma proteins such as albumin (Supplementary Table 4). 
To verify our findings, we focused on new candidates generally not described in the 
context of CKD (lysozyme C, leucine-rich alpha-2-glycoprotein and histidine-rich glycoprotein). 
Using ELISA, we observed in an independent validation cohort that lysozyme C and leucine-rich 
alpha-2-glycoprotein abundance was increased in CKD patients compared to healthy controls, 
and were further increased during HD (Figure 5). Conversely, although histidine-rich 
glycoprotein level was clearly significantly decreased in ESRD as measured using LC-MS/MS, 
we were not able to confirm this difference using ELISA. Such technical discrepancy between 
MS-based and antibody-based approaches such as western blot or ELISA is not uncommon and 
has been observed in other proteome studies24-26, making the validation process, yet necessary, 
sometimes difficult. 
Circulating lysozyme C, a protein released from leukocytes and macrophages and 
primarily known for its bacteriolytic function, binds to the endocardial endothelium and within 
the vascular smooth muscle layer of arteries, leading to the generation of hydrogen peroxide and 
nitric oxide and ultimately causing persistent systemic vasodilatation and myocardial depression 
27, 28. Leucine-rich alpha-2-glycoprotein is a secreted glycoprotein of not too well known 
function and has been linked to different type of cancer, appendicitis and ulcerative colitis29-34. It 
also promotes aberrant angiogenesis35 which is a key feature of a number of diseases including 
age-related macular degeneration, diabetic retinopathy, cancer, atherosclerosis and plaque 
rupture36. Moreover, leucine rich alpha-2 glycoprotein was previously shown to be excreted in 
the urine of patients with IgA nephropathy and CKD37, 38. Plasma accumulation of the proteins 
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was significantly correlated with renal function decline (Supplementary Figure), showing that the 
increased plasma levels of the molecules reflect at least in part alteration of glomerular filtration. 
Although we do not know whether this accumulation can be responsible for the development of 
complications in patients with advanced CKD, it is interesting to note that increased plasma level 
of lysozyme C was significantly associated with atheromatous disease and could predict the 
severity of coronary artery disease39, while increased serum leucine-rich alpha-2-glycoprotein 
has been found to be a biomarker of heart failure29.  
The functional relevance of the 333 proteins identified with our proteomic approach and 
their putative prognostic value, are to be further explored. As a first attempt to gain inside we 
assessed the cellular activities to which these proteins are related with and observed that many of 
them participate in acute phase response and complement and coagulation system activation 
(Figure 3-4, Supplementary Table 5). Activated systemic inflammatory state is a very well-
known epiphenomenon of advanced CKD and dialysis40, 41. The levels of CRP and other acute-
phase reactants proteins such as alpha-1-antichymotrypsin (SerpinA3) and alpha-1-acid 
glycoprotein (Orm1) were increased in our patients with ESRD and HD confirming acute 
inflammatory response in uremic conditions (Figure 4 and Supplementary Table 5). Moreover, 
patients with advanced CKD displayed elevated levels of different members of the complement 
cascade, such as complement components C1r, C1s, C4, C9 and complement factor D. We 
confirmed in the validation cohort that complement factor D abundance was increased in CKD 
patients compared to healthy controls, and was further increased in patients undergoing chronic 
HD (Figure 5). Complement factor D is a serine protease catabolized by the kidney, resulting in 
increased circulating complement factor D concentrations in patients with chronic renal failure 
and on long-term dialysis42. The question remains whether plasma accumulation of complement 
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factor D is only the reflection of an alteration of kidney filtration or is an actor involved in the 
increased risk of CKD associated complications. Although data are scarce, it has been suggested 
that complement factor D might be involved in the development of vascular smooth muscle cells 
abnormalities and arterial cartilaginous lesions in a mouse model of vascular calcifications43, 44. 
In light of our results, further studies should be performed in order to better understand the origin 
and the role complement factor D and complement system in patients with CKD and HD and its 
link to vascular disease. 
In addition to these inflammatory risk factors, changes in the expression of coagulation 
factors F5, F10 and F12, as well as in plasma kallikrein (Klkb1), proteins related to blood 
coagulation and platelet activation (Figure 3B and Supplementary Table 5) were observed. 
Changes in hemostasis are well described in CKD41 due to uremic toxins, interaction with 
dialyzer membranes and the repeated use of anticoagulants all together contributing to the risk of 
cardiovascular and thrombotic complications in patients undergoing HD41. In 1996, Tan et al 
analyzed the plasma activity of different coagulation factors in patients with IgA nephropathy 
and found that IgA patients had significantly lower plasma activity of F12 and Klkb1 compared 
to healthy controls, which was consistent with our observations45. More recently, the plasma 
activity of F5 was found significantly higher in diabetic patients with renal disease compared 
with diabetic patients without renal disease46, a finding in accordance with the observed 
increased level of F5 in the plasma of CKD patients.  However, in this study, plasma activity of 
F10 tended to decrease as observed in our study but this not reached significant level46. 
One of the main limitations of this study is that observed molecular changes have not 
been related to clinical endpoints such as infections, hemorrhages, atherosclerosis or 
cardiovascular events except for leucine-rich alpha-2 glycoprotein for which we observed that 
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high plasma levels are significantly associated with higher mortality in patients with CKD5 on 
hemodialysis compared to patients with low leucine-rich alpha-2 glycoprotein abundance (Figure 
6C). Indeed, this study was designed as a discovery study to first identify new candidate proteins 
among a broad array of hundreds of potential candidates with significant plasma changes, which 
may in subsequent studies enable better understanding of HD-associated complications.  
In conclusion, in this study we have generated for the first time a comprehensive 
assessment of the plasma proteome of ESRD patients in comparison to early stage CKD, in a 
cohort of significant size that enabled identification of a large array of proteins altered in ESRD, 
using high-resolution LC-MS/MS analysis. This study serves as a basis for future studies 
investigating the relevance of the observed changes, but also as a well-defined comparator for 
similar studies in the future. In addition, the data may serve for further biomarker identification 
and systems biology-based assessment of the molecular mechanisms involved CKD-associated 
morbidity and mortality. 
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Table 1. Patient selection. The table summarizes the demographic and clinical data of the patients included in the study. n.d.: not detected. n.s: not 
significant. n.a.: not available. 
 Discovery cohort (complete)  Discovery sub cohort (matched)  Validation cohort 
  CKD2-3 CKD5/HD  pValue   CKD2-3 CKD5/HD  pValue   Controls CKD3b CKD4 CKD5 no HD CKD5/HD pValue 
N 14 15   7 7   8 8 8 8 8  
Male/Female 6/8 12/3 0.039  3/4 4/3 n.s.  4/4 4/4 4/4 4/4 4/4 n.s. 
eGFR (mL/min/1.73m²) 63.78 ±14.42 9.13 ± 3.20 <0.0001  
61.30 
±12.39 <10 0.0006  - 37.05 ±4.00 21.81 ±5.46 12.17 ±2.21 <10 <0.0001 
Proteinuria (Yes/No) 2/12 n.a.   0/7 n.a.   n.a. 5/3 3/3 (2 n.a.) 5/1 (2 n.a.) n.a.  
Age (years) 57.16 ±11.63 70.33 ±8.49 0.004  
64.51 
±8.57 65.45 ±9.67 n.s.  50.64 ±13.25 60.08 ±10.33 57.92 ±14.66 63.17 ±20.48 59.67 ±10.46 n.s. 
Time on dialysis (year) - 2.58 ±2.57   - 3.00 ±3.21   - - - - 5.17 ±4.32  
BMI (kg/m²) 29.39 ±6.79 25.81 ±4.78 n.s.  
30.99 
±6.99 26.63 ±6.22 n.s.  23.97 ±4.62 26.88 ±3.96 26.87 ±4.01 27.10 ±5.13 29.55 ±7,98 n.s. 
Systolic blood pressure 
(mmHg) 134±15 150±19 0.032  144±14 154±10 n.s.  124±14 143±21 139±19 128±10 143±16 0.017 
Diastolic blood pressure 
(mmHg) 71±8 77 ±9 n.s.  74±8 78±10 n.s.  75 ±9 82 ±9 84 ±12 80 ±6 71 ±16 n.s. 
C-Reactive Protein 
(mg/L) 
2.71 
±2.71 
13.35 
±14.26 0.003  3.43 ±3.14 
16.46 
±15.72 n.s.  2.22 ±1.52 2.75 ±2.22 3.00 ±1.21 3.25 ±4.75 6.2    ±6.12 n.s. 
Etiologies               
   Diabetes 4 7 
n.s. 
 3 4 
n.s. 
 - 2 1 1 2 
n.s. (between all 
groups) 
   Vascular 4 3  4 2  - 0 3 1 2 
   Glomerular 1 2  0 0  - 2 1 2 0 
   ADPKD 0 0  0 0  - 2 0 2 2 
   Other/Unknown 5 3  0 1  - 2 3 2 2 
Medications (%)               
   Vitamin K anta 7 7 n.s.  14 0 n.s.  0 25 13 0 0 n.s. 
   Antiaggregant 0 53 0.0022  0 43 n.s.  0 63 63 50 25 0.044 
   ACEi/ARB 36 33 n.s.  43 29 n.s.  25 75 63 88 50 n.s. 
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   Statin 21 33 n.s.  29 29 n.s.  13 50 50 88 50 n.s. 
   Cortisone 0 0 n.s.   0 0 n.s.   0 0 0 0 0 n.s. 
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Table 2. Plasma proteome changes in CKD2-3 versus CKD5/HD patients. List of 39 modified proteins identified with LC-MS/MS 
in the complete discovery cohort (adjusted pValue<0.05) and in the age- and sex- matched sub cohort. Bold: protein validated with 
ELISA in the validation cohort. n.d.: not detected. n.s.: not significant. 
  Discovery cohort (complete) 
 
Discovery sub cohort (matched) 
Symbol Name 
Molecular 
weight 
(kDa) 
Fold change Direction Unadjusted pValue 
Adjusted 
pValue   Fold change Direction 
Unadjusted 
pValue 
IGFBP6 Insulin-like growth factor-binding protein 6 23 n.d. in CKD2-3 Up 0,0001 0,0128  n.d. in CKD2-3 Up 0,0156 
LYZ Lysozyme C 15 n.d. in CKD2-3 Up 0,0002 0,0187  n.d. in CKD2-3 Up 0,0156 
B2M Beta-2-microglobulin 12 99,03 Up 0,0000 0,0105  68,3 Up 0,0170 
CFD Complement factor D 24 97,8 Up 0,0000 0,0044  n.d. in CKD2-3 Up 0,0156 
PTGDS Prostaglandin-H2 D-isomerase 19 32,36 Up 0,0003 0,0245  37,36 Up 0,0364 
PRPF3 U4/U6 small nuclear ribonucleoprotein Prp3 78 28,16 Up 0,0001 0,0150  20,4 Up 0,0265 
WDFY4 WD repeat- and FYVE domain-containing protein 4 354 7,82 Up 0,0002 0,0204  18,77 Up 0,0088 
RUSC2 Iporin 161 6,02 Up 0,0000 0,0012  16,41 Up 0,0003 
C1S Complement C1s subcomponent 47 & 28 4,54 Up 0,0001 0,0128  3,7 Up 0,0018 
SSX2IP Afadin- and alpha-actinin-binding protein 71 4,53 Up 0,0001 0,0114  4,04 Up n.s. 
LENG8 Leukocyte receptor cluster member 8 86 4,41 Up 0,0000 0,0044  4,17 Up 0,0009 
AMBP Protein AMBP 21 & 16 & 7 3,98 Up 0,0000 0,0039  4,05 Up 0,0004 
CCDC147 Coiled-coil domain-containing protein 147 103 3,57 Up 0,0002 0,0180  6,53 Up 0,0121 
SETD2 Histone-lysine N-methyltransferase SETD2 288 3,37 Up 0,0009 0,0499  3,21 Up 0,0282 
NR0B1 Nuclear receptor subfamily 0 group B member 1 52 3,15 Up 0,0001 0,0128  5,18 Up 0,0007 
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C1R Complement C1r sucomponent 51 & 27 3 Up 0,0001 0,0123  2,46 Up 0,0271 
HBB Hemoglobin subunit beta 16 2,85 Up 0,0006 0,0403  5,53 Up 0,0036 
CNNM4 Metal transporter CNNM4 87 2,55 Up 0,0002 0,0204  1,97 Up n.s. 
SLC9A5 Sodium/hydrogen exchanger 5 99 2,23 Up 0,0002 0,0167  2,69 Up 0,0028 
TFAM Transcription factor A, mitochondrial 24 2,15 Up 0,0007 0,0427  2,28 Up 0,0094 
ITPR1 Inositol 1,4,5-trisphosphate receptor type 1 314 2,01 Up 0,0006 0,0394  1,75 Up 0,0133 
SERPINF1 Pigment epithelium-derived factor 44 1,92 Up 0,0003 0,0228  2,63 Up 0,0037 
IGHA1 Ig alpha-1 chain C region 38 1,88 Up 0,0006 0,0403  1,66 Up 0,0096 
CSPP1 Centrosome and spindle pole-associated protein 1 146 0,64 Down 0,0008 0,0459  0,77 Down n.s. 
LRRIQ3 Leucine-rich repeat and IQ domain-containing protein 3 74 0,6 Down 0,0003 0,0210  0,62 Down 0,0194 
FNBP1 Formin-binding protein 1 71 0,54 Down 0,0001 0,0134  0,54 Down 0,0025 
RLTPR Leucine-rich repeat-containing protein 16C 155 0,5 Down 0,0003 0,0242  0,56 Down 0,0283 
HRG Histidine-rich glycoprotein 58 0,47 Down 0,0006 0,0403  0,39 Down 0,0153 
F12 Coagulation factor XII 40 & 26 0,46 Down 0,0009 0,0472  0,45 Down 0,0306 
ARHGAP25 Rho GTPase-activating protein 25 73 0,42 Down 0,0008 0,0472  0,7 Down n.s. 
SNIP1 Smad nuclear-interacting protein 1 46 0,37 Down 0,0002 0,0179  0,42 Down 0,0281 
ZNF415 Zinc finger protein 415 69 0,3 Down 0,0007 0,0427  0,13 Down 0,0018 
CALR3 Calreticulin-3 43 0,29 Down 0,0009 0,0499  0,24 Down 0,0135 
ZFAND4 AN1-type zinc finger protein 4 80 0,23 Down 0,0000 0,0014  0,28 Down 0,0087 
NOS2 Nitric oxide synthase, inducible 131 0,16 Down 0,0000 0,0044  0,31 Down 0,0255 
GPX3 Glutathione peroxidase 3 23 0,15 Down 0,0000 0,0012  0,13 Down 0,0021 
PDE4B cAMP-specific 3,5-cyclic phosphodiesterase 4B 83 0,15 Down 0,0001 0,0128  0,07 Down 0,0009 
SBF1 Myotubularin-related protein 5 208 0,05 Down 0,0000 0,0044  0,08 Down 0,0042 
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MIPEP Mitochondrial intermediate peptidase 77 0,01 Down 0,0001 0,0105   0,01 Down 0,0421 
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Figure legends 
Figure 1. Overview of the study design. 
Figure 2. Correlation of quantification of plasma proteins identified using LC-MS/MS with 
their plasma concentrations. A. Correlation of the published concentrations of the 20 most 
abundant plasma proteins as measured in the standard plasma using immune assays to their 
relative LC-MS/MS abundance in the plasma of the CKD2-3 or CKD5/HD patients as quantified 
in our study using the normalized-ppm mass-peak area (arbitrary units). B. Correlation of the 
absolute concentration of C-reactive protein (CRP) to its relative LC-MS/MS abundance in the 
plasma of the CKD2-3 or CKD5/HD patients. 
Figure 3. Alteration of the complement and coagulation systems. Simplified view of the 
complement (A) and coagulation (B) systems using Ingenuity pathway designer. Grey: not 
modified; Green: decreased abundance; Red: increased abundance; White: not detected with LC-
MS/MS; Oval shape: pathway-specific proteins; Square shape: proteins shared with different 
pathways. 
Figure 4. Alteration of the acute phase response pathway. Simplified view of the acute phase 
response signaling pathway using Ingenuity pathway designer. Grey: not modified; Green: 
decreased abundance; Red: increased abundance; White: not detected with LC-MS/MS; Oval 
shape: pathway-specific proteins; Square shape: proteins shared with different pathways.  
Figure 5. Validation of plasma protein modifications during CKD progression and HD. 
Plasma changes of complement factor D (A, E), lysozyme C (B, F), leucine-rich alpha-2-
glycoprotein (C, G), and histidine-rich glycoprotein (D, H) identified with high confidence using 
LC-MS/MS were confirmed using ELISA in an independent validation cohort of healthy controls 
(n=8), and patients with CKD3b (n=8), CKD4 (n=8), CKD5 not in HD (CKD5 no HD, n=8) and 
CKD5 with HD (CKD5/HD, n=8). *p<0.05; ****p<0.0001. 
Figure 6. Association of plasma protein levels with mortality in CKD5/HD patients. 
Survival analysis was performed on CKD5/HD patients from the discovery cohort stratified 
based on high (solid line) versus low (dashed line) LC-MS/MS abundance of complement factor 
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D (High n=6; Low n=7) (A), lysozyme C (High n=6; Low n=7) (B), leucine-rich alpha-2-
glycoprotein (High n=6; Low n=7) (C) and histidin-rich glycoprotein (High n=6; Low n=7) (D). 
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Supporting Information.  
Supplementary Figure. Correlation of plasma protein concentrations to eGFR. Plasma 
concentrations of complement factor D, lysozyme C, leucine-rich alpha-2-glycoprotein and 
histidine-rich glycoprotein using ELISA was correlated to eGFR in the independent validation 
cohort.  
 
Supplementary Table 1. Peptide identification using LC-MS/MS. The table displays the 
complete list of 9017 tryptic peptides identified using LC-MS/MS associated with their relative 
abundance (expressed using normalized-ppm mass-peak area (arbitrary units)) and their 
regulation in the CKD5/HD group compared with CKD2-3 group.  
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Supplementary Table 2. Protein identification using LC-MS/MS. The table displays the 
complete list of 2054 proteins identified using LC-MS/MS by combination of tryptic peptides, 
their relative abundance (expressed in ppm) and their regulation in the CKD5/HD group 
compared with CKD2-3 group.  
 
Supplementary Table 3. Highly abundant plasma proteins. The table displays the list of the 
20 most abundant plasma proteins associated with their respective published concentrations as 
measured in the standard plasma using immune assays and their relative LC-MS/MS abundance 
in the plasma of the CKD2-3 or CKD5/HD patients as quantified in our study using the 
normalized-ppm mass-peak area (arbitrary units). 
 
Supplementary Table 4. LC-MS/MS detection of uremic toxins. The table displays the 25 
known low-molecular weight proteins that accumulate in uremic syndrome, their reported 
normal and uremic concentrations as reviewed in Duranton et al., 2012 (PMID: 22626821) and 
Vanholder et al., 2003 (PMID: 12675874) and their detection using LC-MS/MS. 
 
Supplementary Table 5. Functional analysis of plasma proteome changes. List of functional 
pathways modified using Gene Ontology (GO) and Ingenuity Pathway Analysis software (IPA) 
associated with significantly modified proteins. Bold: proteins with adjusted pValue<0.05. 
 
 
 
